The European market for antisera and related products shows significant variability by country. In 2023, Ireland dominated, contributing the largest share, followed by France and Belgium. Notably, Belgium's production surged by over 70%, while France saw an increase of nearly 34%. Conversely, the UK and Denmark experienced declines, with the UK dropping over 11%. Other notable players include Sweden and Germany, albeit with modest growth. This suggests a dynamic shift in market leadership, with Belgium and France rapidly gaining prominence.
Looking ahead, the European market is poised for further shifts as innovation, regulatory changes, and health priorities evolve. Continuous monitoring of emerging economies and technological advancements will be crucial in predicting future growth patterns and market share shifts in this sector.
Top countries in Sold Production of Antisera, Other Immunological Products and Other Blood Fractions Share by Country (Euros)
| # | 10 Countries | Percent | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Ireland | 64.15 | 2023 | +5.93% | +5.75% | View data |
| 2 | 2 France | 15.9 | 2023 | +17.97% | +33.89% | View data |
| 3 | 3 Belgium | 11.52 | 2023 | +27.11% | +70.47% | View data |
| 4 | 4 Sweden | 6.64 | 2023 | +22.29% | +27.49% | View data |
| 5 | 5 Germany | 5.13 | 2023 | +1.51% | +3.02% | View data |
| 6 | 6 Austria | 1.93 | 2021 | +43.48% | View data | |
| 7 | 7 Spain | 1.14 | 2023 | -3.82% | +4.18% | View data |
| 8 | 8 United Kingdom | 1.09 | 2023 | -4.22% | -11.23% | View data |
| 9 | 9 Finland | 0.21 | 2023 | +10.05% | +3.4% | View data |
| 10 | 10 Denmark | 0.06 | 2023 | +7.82% | -14.22% | View data |
